single_man
Print Page    E-mail Page    RSS    E-mail Alerts 

Investors

Corporate Profile

At Bellerophon Therapeutics, we aim to transform the lives of people suffering from cardiopulmonary and cardiac diseases by developing innovative therapies at the intersection of drugs and devices for these therapeutic areas and to do so while serving the best interests of our shareholders.

...
more >
Stock Quotemore >
$1.39
 Stock is Down 0.05 (3.47%)
Bellerophon (Nasdaq: BLPH)
Data as of 09/30/16 12:27 p.m. ET
Minimum 20 minute delay
Recent Newsmore >
09/20/16
Bellerophon Therapeutics Announces Planned Management Transition by Year-End 2016
WARREN, N.J., Sept. 20, 2016 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced the planned transition of Fabian Tenenbaum, current Chief Financial Officer and Chief Business Officer, to Chief Executive Officer of the company, succeeding Jonathan Peacock, who will retain his position as Chairman of the Board and remain actively involved. The transition will be completed by year-end. Commenting on the management transit... 
09/06/16
Bellerophon to Present at the 18th Annual Rodman & Renshaw Global Investment Conference
WARREN, N.J., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that it will present at the 18th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held at Lotte New York Palace Hotel in New York City. Bellerophon management will provide a Company update during the live presentation and will be available to participate in one-on... 
08/09/16
Bellerophon Reports Second Quarter 2016 Financial Results and Provides Business Update
WARREN, N.J., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today reported financial results for the second quarter ended June 30, 2016 and provided a business update. “This quarter, we made important progress on our development plans across our clinical pipeline,” stated Jonathan Peacock, Chairman and Chief Executive Officer of Bellerophon Therapeutics. “As planned, in June we enrolled our first patient in our Phase ... 
Upcoming Eventsmore >
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources